Browsing College of Medicine by Subject "PD-L1"
Now showing items 1-8 of 8
-
Abstract B094: Novel method for patient stratification in breast carcinoma based upon spatial analysis of tumor microenvironment
( American Association for Cancer Research , 2019 , Conference Paper)Breast cancer consists of several intrinsic molecular subtypes, providing the basis for clinical treatment decisions. Lately, it is becoming increasingly recognized that factors other than the intrinsic cancer characteristics, ... -
Comment on the manuscript “Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma” by Salisbury et al. (Ann Diagn Pathol 2022; 57: 151901, https://doi.org/10.1016/j.anndiagpath.2022.151901)
( Elsevier , 2022 , Other)I read with great interest a recent paper written by Salisbury et al. published in the April 2022 issue of the Annals of Diagnostic Pathology [1]. In their study, the authors explored a small cohort of triple-negative ... -
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
( Elsevier , 2018 , Article)Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in NSCLC, ... -
Mycoplasma bovis-induced inhibition of bovine peripheral blood mononuclear cell proliferation is ameliorated after blocking the immune-inhibitory programmed death 1 receptor
( American Society for Microbiology , 2018 , Article)Mycoplasma bovis-induced immune suppression is a major obstacle faced by the host for controlling infections. M. bovis impairment of antigen-specific T-cell responses is achieved through inhibiting the proliferation of ... -
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
( AME Publishing Company , 2017 , Article)CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors -
PD-L1 status in breast cancer: Current view and perspectives.
( Elsevier , 2019 , Article)Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ... -
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2022 , Article Review)Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ... -
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2019 , Article Review)The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ...